ADC Therapeutics Reports 89.8% Response Rate in ZYNLONTA and Glofitamab Phase 1b Trial for r/r DLBCL
I'm PortAI, I can summarize articles.
ADC Therapeutics announced updated results from the LOTIS-7 Phase 1b trial, showing an 89.8% overall response rate and 77.6% complete response rate for ZYNLONTA and glofitamab in r/r DLBCL patients. The combination therapy demonstrated a manageable safety profile, with grade 5 adverse events in 4.1% of patients and cytokine release syndrome in 36.7%. The data was presented by the company and published via EDGAR.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments